Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Shares of MBX Biosciences , which is developing therapies that target endocrine and metabolic disorders, including diabetes and obesity, jumped nearly 44% in their Nasdaq debut on Friday. https://t.co/RiCcsmrfUW https://t.co/RiCcsmrfUW
๐ MBX Biosciencesโ shares surged nearly 44% on their Nasdaq debut, highlighting growing investor interest in weight-loss and metabolic disorder therapies.๐๐ . . . #MBXBiosciences #IPO #BiotechStocks #WeightLossDrugs Read๐ https://t.co/MawqUlTc9J
๐ Congratulations to @BicaraTx on your @Nasdaq IPO! ๐ We are thrilled to celebrate this milestone with you and are proud to support your innovative efforts in advancing bifunctional immuno-oncology therapies... https://t.co/SKuJ1lRKNw
MBX Biosciences made a notable debut on the Nasdaq Exchange with an IPO on Friday, with shares surging nearly 44% on their first day of trading. The company, which focuses on developing therapies for endocrine and metabolic disorders such as diabetes and obesity, has attracted significant investor interest. This highlights a growing trend in the biotech sector, particularly in weight-loss and metabolic disorder therapies.
